Literature DB >> 19795190

Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?

Steven B Deitelzweig1, Jay Lin, Mohamed Hussein, David Battleman.   

Abstract

The US Surgical Care Improvement Project (SCIP) has approved two performance measures to improve venous thromboembolism (VTE) prevention. SCIP-VTE-2 measures the proportion of surgery patients who received appropriate VTE prophylaxis within 24 h prior to surgery to 24 h after surgery. This study assesses the current rate of achievement of SCIP-VTE-2 criteria using a retrospective data set of real-world surgical patients. The Premier Perspective database, which contains real-world data from >400 US hospitals, was queried (January 2004-December 2006) for in-patient hospital transactional billing records of surgical patients aged >or=18 years. The primary outcome was the proportion of patients achieving SCIP-VTE-2 requirements for appropriate and timely prophylaxis as per the SCIP-VTE-2 algorithm. Of the 149,785 patients included, 56.2% received appropriate prophylaxis and 52.7% achieved the SCIP-VTE-2 performance measure for both appropriate and timely prophylaxis. To conclude, this study highlights that VTE prophylaxis currently only meets SCIP-VTE-2 requirements in approximately half of real-world surgical patients. The use of retrospective analyses such as this hospital billing data analysis may assist hospitals in measuring their current and future performance in VTE prevention.

Entities:  

Mesh:

Year:  2010        PMID: 19795190     DOI: 10.1007/s11239-009-0393-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  10 in total

1.  Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.

Authors:  Adrienne Heerey; Sanjeev Suri
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.

Authors:  Alex C Spyropoulos; Jay Lin
Journal:  J Manag Care Pharm       Date:  2007 Jul-Aug

3.  Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis?

Authors:  Alpesh N Amin; Stephen Stemkowski; Jay Lin; Guiping Yang
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

4.  Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.

Authors:  David A MacDougall; Anthony L Feliu; Stephen J Boccuzzi; Jay Lin
Journal:  Am J Health Syst Pharm       Date:  2006-10-15       Impact factor: 2.637

Review 5.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

6.  Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty.

Authors:  Richard J Friedman; Alexander S Gallus; Fred D Cushner; Gordon Fitzgerald; Frederick A Anderson
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

7.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism.

Authors:  Frederick A Anderson; Maxim Zayaruzny; John A Heit; Dogan Fidan; Alexander T Cohen
Journal:  Am J Hematol       Date:  2007-09       Impact factor: 10.047

9.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.

Authors:  Alexander T Cohen; Victor F Tapson; Jean-Francois Bergmann; Samuel Z Goldhaber; Ajay K Kakkar; Bruno Deslandes; Wei Huang; Maksim Zayaruzny; Leigh Emery; Frederick A Anderson
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

10.  Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.

Authors:  Marc F Botteman; Joseph Caprini; Jennifer M Stephens; Vijay Nadipelli; Christopher F Bell; Chris L Pashos; Alexander T Cohen
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

  10 in total
  3 in total

1.  Perioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgery.

Authors:  Steve Kwon; Mark Meissner; Rebecca Symons; Scott Steele; Richard Thirlby; Rick Billingham; David R Flum
Journal:  J Am Coll Surg       Date:  2011-08-25       Impact factor: 6.113

2.  The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis.

Authors:  Patricia C Henwood; Thomas M Kennedy; Lynda Thomson; Taki Galanis; George L Tzanis; Geno J Merli; Walter K Kraft
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

3.  Perioperative management of gynecological surgery patients: does fellow involvement improve performance?

Authors:  Holly L Steiner; Catrina C Crisp; Rachel N Pauls
Journal:  Int Urogynecol J       Date:  2012-11-14       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.